首页> 外文期刊>EFSA Journal >Scientific Opinion on applications (EFSA‐GMO‐RX‐MON863) for renewal of the authorisation for continued marketing of existing feed materials, feed additives and food additives produced from maize MON863, under Regulation (EC) No 1829/2003 from Monsanto
【24h】

Scientific Opinion on applications (EFSA‐GMO‐RX‐MON863) for renewal of the authorisation for continued marketing of existing feed materials, feed additives and food additives produced from maize MON863, under Regulation (EC) No 1829/2003 from Monsanto

机译:关于根据孟山都(EC)第1829/2003号法规(EC)续签继续销售由玉米MON863生产的现有饲料原料,饲料添加剂和食品添加剂的授权的申请的科学意见(EFSA-GMO-RX-MON863)

获取原文
       

摘要

This scientific opinion reports on an evaluation of an application (reference EFSA‐GMO‐RX‐MON863_([8.1.b/20.1.b])) for renewal of the authorisation for continued marketing of existing feed materials, feed additives and food additives produced from genetically modified (GM) insect resistant maize MON863. Maize MON863 has been modified with a gene encoding the Cry3Bb1 protein which confers protection against coleopteran pests, principally the corn rootworm (Diabrotica spp.). In addition, a selectable marker gene npt II encoding neomycin phosphotransferase II has been introduced. In 2004 the EFSA GMO Panel issued scientific opinions on a Notification for the placing on the market of GM maize MON863 for import and processing and on a request from the European Commission for the placing on the market of foods and food ingredients derived from GM maize MON863. In delivering the present opinion, the EFSA GMO Panel considered the information provided in the application EFSA‐GMO‐RX‐MON863_([8.1.b/20.1.b]) as well as additional information provided by the applicant and information published in the scientific literature. The new data in the application included bioinformatic analyses using updated databases which confirmed that no relevant similarities exist between the newly expressed proteins and known allergens or proteins toxic to mammals. The EFSA GMO Panel has evaluated the new information provided by the applicant and the scientific literature and concluded that there was no new information that would require changes of its previous scientific opinions on maize MON863 (EFSA, 2004a,b). Therefore, the EFSA GMO Panel reiterates its previous conclusions that GM maize MON863 and its products which are the subject of this application are unlikely to have an adverse effect on human and animal health or the environment in the context of its intended uses (EFSA, 2004a,b).
机译:该科学意见报告了对申请的评估(参考EFSA-GMO-RX-MON863 _([8.1.b / 20.1.b])),以续签继续销售现有饲料原料,饲料添加剂和食品添加剂的许可来自转基因(GM)昆虫抗性玉米MON863。玉米MON863已经用编码Cry3Bb1蛋白的基因修饰,该蛋白赋予对鞘翅目害虫,主要是玉米根虫(Diabrotica spp。)的保护。另外,已经引入了编码新霉素磷酸转移酶II的选择标记基因npt II。 2004年,欧洲食品安全局(EFSA)GMO小组就转基因玉米MON863供进口和加工的上市通知以及欧洲委员会关于转基因玉米MON863的食品和食品成分投放市场的要求发布了科学意见。 。在发表当前意见时,EFSA GMO小组考虑了应用程序EFSA-GMO-RX-MON863 _([8.1.b / 20.1.b])中提供的信息,以及申请人提供的其他信息以及在科学文学。该应用程序中的新数据包括使用更新的数据库进行的生物信息学分析,这证实了新表达的蛋白质与已知的变应原或对哺乳动物有毒的蛋白质之间不存在相关相似性。 EFSA GMO小组评估了申请人提供的新信息和科学文献,并得出结论,没有新的信息需要改变其对玉米MON863的先前科学观点(EFSA,2004a,b)。因此,EFSA GMO小组重申其先前的结论,即本申请主题的转基因玉米MON863及其产品在其预期用途的范围内不太可能对人类和动物健康或环境产生不利影响(EFSA,2004a ,b)。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号